The new article "Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms" by Olga Ivanova and Tatiana Karelina was published in PSPJournal at the end of August 2024.
Olga Ivanova comments on the article, "Our model of PD-like pathology in mice captures the complex dynamics of αSyn metabolism throughout the brain and the influence of neuroinflammation on PD pathogenesis and dopaminergic neurodegeneration. The model simulations predict how different proposed mechanisms of anti-αSyn immunotherapy may contribute to pathology reduction and how anti-inflammatory therapy may enhance the effect of immunotherapy."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2024 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
1.
11 Jun 2024 18:28
InSysBio to participate in JuliaCon2024
InSysBio announces its participation in JuliaCon2024 which is to be held from July 9-13, 2024, at the Philips Stadion, Eindhoven, the Netherlands. Ivan Borisov, Senior Software Developer at InSysBio, will give a lightning talk "Profile Likelihood-based Practical Identifiability in Julia". Moreover, InSysBio team is going to present 2 posters in frames of the Conference
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
Thank you for your message! We will get back to you shortly.
